| Application no. and date | 18785191.0 (espacenet) (Federated) (European Patent Register), 20180409 | | Patent/reg. no. and date | DK/EP 3609495, 20240724 | | Publication date | 20200219 | | Priority no. and date | US 201762483555 P, 20170410 | | EP pub. no. and date |
EP 3609495 20200219 | | Effective date | | | Applicant/owner | Chase Therapeutics Corporation, 1825 K Street N.W.
Suite 520
Washington, DC 20006, US | | Applicant ref. no. | | | Inventor | CHASE, Thomas N., 1825 K Street NW
Suite 520
Washington, District of Columbia 20006, US,
CLARENCE-SMITH, Kathleen E., 1825 K Street NW
Suite 520
Washington, District of Columbia 20006, US | | Representative | | | Opponent | | | IPC Class | A61K 31/428 (2006.01) , A61K 31/5377 (2006.01) , A61K 31/675 (2006.01) , A61P 25/00 (2006.01) , A61P 25/16 (2006.01) , A61P 25/28 (2006.01) | | Title | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | | Int. application no. | US2018026699 | | Int. publication no. | WO2018191160 | | Related patent (certificate) | | | Status | Enhedspatent registreret | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
